FAQsCOVID-19 Testing Frequently Asked Questions
FREQUENTLY ASKED QUESTIONS
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is caused by the Corona virus 2019 (COVID-19), a new strain of coronavirus that has not been previously known to infect humans. The virus is the cause of outbreaks of respiratory illness in multiple locations around the world, including the U.S.
For the most up to date information on COVID-19, please visit the CDC Coronavirus Disease 2019 (COVID-19) general webpage: https://www.cdc.gov/COVID19
Individuals with COVID-19 have had a wide range of symptoms reported – ranging from mild symptoms to severe illness.
According to the CDC, symptoms may appear 2-14 days after exposure to the virus. According to the CDC, people with these symptoms may have COVID-19:
- Shortness of breath or difficulty breathing
- Muscle pain
- Sore throat
- New loss of taste or smell
This list is not all possible symptoms. Other less common symptoms have been reported, including gastrointestinal symptoms like nausea, vomiting, or diarrhea.
For the most current information regarding COVID-19 symptoms, please refer to the CDC Symptoms webpage: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
CRL offers multiple testing solutions for determining COVID-19 status:
CRL CLEAR™ Results of antibody testing can confirm the presence, or lack of, COVID antibodies in the individual. All positive antibody tests should be reflexed to a molecular test to confirm if active virus is present. Supported specimen types include:
- Dried blood spot (DBS) finger stick – a lab developed finger stick test for asymptomatic populations that can be self-administered and shipped to the lab for testing.
- Venipuncture serum – an FDA EUA approved venipuncture serum antibody test that is administered by a health professional and shipped to the lab for testing.
CRL RAPID RESPONSE™ An FDA EUA approved saliva-based molecular test that is easily self-collected and shipped to our lab. Results of the test confirm if the virus is detected in the saliva of the individual.
Contact the individual who provided the kit and request a new one.
NOTE: The laboratory will be unable to process your sample unless the kit is registered at crlclear.com. For molecular saliva-based tests, make sure to adhere barcode label sticker to the saliva tube before shipping sample to the lab.
If the camera on your mobile device is not reading the barcode, please input the barcode number manually.
If the entered barcode number returns the message “invalid barcode value!” please contact customer service at CTsupport@crlcorp.com.
Your kit includes a transport bag and a pre-labeled Clinical Reference Laboratory transport box. Package your sample as instructed and drop off at any FedEx Ship Location. Or you can request that your sample be picked up by scheduling a time with FedEx. In the United States, call FedEx at 1-800-463-3339 for pickup. Specify you have a prepaid shipment for overnight delivery.
Note: Saliva samples must be shipped within 24 hours of collection.
Typically, results are available within 24 hours for antibody tests and within 48 hours for molecular tests, once received at the laboratory.
Your result will be delivered directly to you via phone – mobile or landline – as soon as it is available. If you provided a telephone number during registration, you will be contacted via text, or voice message when the result is available. Before viewing the result, you will be prompted to complete a dual factor authentication process.
Molecular Test: Molecular results to determine active virus are reported detected (positive) or non-detected (negative). Molecular testing provides evidence of an active, or recent infection. The molecular test does not provide a quantitative level of the virus or indicate the severity of the infection.
Antibody Test: Antibody results are reported as reactive (positive) or non-reactive (non-detected). Antibody testing provides evidence that a patient may have been exposed to the SARS-CoV-2 virus. The antibody test does not provide a quantitative result (i.e. antibody tier) nor differentiation of the sub-types. It does not exclude the possibility of a recent infection.